DeepMed Research

Linifanib

Generic Name: Linifanib

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₁₈FN_₅O

CAS Number: 796967-16-3

Unique Ingredient Identifier: CO93X137CW

Background: Linifanib (ABT-869) is a small molecule vascular endothelial growth factor (VEGF) receptor-based kinase inhibitor that is designed to suppress tumor growth by preventing the formation of new blood vessels that supply the tumor with oxygen and nutrients and by inhibiting key angiogenic signaling pathways. Linifanib is intended for the treatment of hematologic malignancies and the solid tumors.

Indication: Investigated for use/treatment in leukemia (myeloid), myelodysplastic syndrome, and solid tumors.

Clinical Trials

A Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors

Phase 1

Terminated

Conditions: Advanced or Metastatic Solid Tumors

Interventions: Drug: linifanib

First Posted Date: 2012-01-10

Last Posted Date: 2012-08-28

Lead Sponsor: Abbott

Target Recruit Count: 14

Registration Number: NCT01506934

Locations: 🇺🇸
Site Reference ID/Investigator# 61282, Detroit, Michigan, United States
🇺🇸
Site Reference ID/Investigator# 52122, San Antonio, Texas, United States
🇺🇸
Site Reference ID/Investigator# 51463, Lebanon, New Hampshire, United States

and more 1 locations

An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: linifanib

First Posted Date: 2011-08-10

Last Posted Date: 2017-11-21

Lead Sponsor: AbbVie

Target Recruit Count: 35

Registration Number: NCT01413893

Effect of Rifampin on the Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: Linifanib
Drug: Rifampin

First Posted Date: 2011-07-26

Last Posted Date: 2011-11-02

Lead Sponsor: Abbott

Target Recruit Count: 14

Registration Number: NCT01401933

Locations: 🇺🇸
Site Reference ID/Investigator# 49952, Madison, Wisconsin, United States
🇺🇸
Site Reference ID/Investigator# 49953, Tucson, Arizona, United States

To Compare Relative Bioavailability of Two Clinical Formulations of Linifanib.

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: linifanib

First Posted Date: 2011-06-27

Last Posted Date: 2012-03-23

Lead Sponsor: Abbott

Target Recruit Count: 13

Registration Number: NCT01381341

Locations: 🇺🇸
Site Reference ID/Investigator# 51403, Tacoma, Washington, United States

Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer

Phase 2

Terminated

Conditions: Stage IVA Colon Cancer
Stage IVA Rectal Cancer
Recurrent Colon Cancer
Recurrent Rectal Cancer
Stage IVB Colon Cancer
Stage IVB Rectal Cancer

Interventions: Drug: linifanib

First Posted Date: 2011-06-03

Last Posted Date: 2014-08-26

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 30

Registration Number: NCT01365910

Locations: 🇺🇸
Vanderbilt Cool Springs, Franklin, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

A Pharmacokinetic Study to Access How the Body Absorbs and Removes Linifanib in Male Patients With Advanced Solid Tumors.

Phase 1

Terminated

Conditions: Advanced Solid Tumors

Interventions: Drug: ABT-869, linifanib
Drug: [14C]linifanib

First Posted Date: 2011-02-01

Last Posted Date: 2012-09-21

Lead Sponsor: Abbott

Target Recruit Count: 3

Registration Number: NCT01286974

Locations: 🇺🇸
Site Reference ID/Investigator# 40942, Cleveland, Ohio, United States
🇺🇸
Site Reference ID/Investigator# 53663, Cleveland, Ohio, United States

A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Linifanib
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2010-10-21

Last Posted Date: 2017-11-21

Lead Sponsor: AbbVie

Target Recruit Count: 12

Registration Number: NCT01225302

WALTZ - Wet Age-Related Macular Degeneration (AMD) AL-39324 Treatment Examination

Phase 2

Completed

Conditions: Age Related Macular Degeneration

Interventions: Drug: AL-39324 ophthalmic suspension
Drug: Ranibizumab 10 mg/mL

First Posted Date: 2009-10-09

Last Posted Date: 2014-07-18

Lead Sponsor: Alcon Research

Target Recruit Count: 35

Registration Number: NCT00992563

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy